retatrutide clinical trial results 2024 2025 press release 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Eli Lilly touts strong results

The latest number that Novo disclosed in February is that more than 600,000 prescriptions had been written since its launch, including for more than 3,000 patients in the first week

[DOI] [PMC free article] [PubMed] [Google Scholar] 13.van Bloemendaal L., ten Kulve J.S., La Fleur S.E., Ijzerman R.G., Diamant M

Just a heads-up the link will expire in 24 hours Hydro-Facial Machine Ebook 25.00 Learn how to confidently and effectively use the hydro-facial machine with ease

Lower treatment burden While retatrutide shows significant promise, Eli Lilly is likely to disrupt the market more imminently and more substantially following the launch of orforglipron in early 2026

Just make sure its fat and not muscles getting depleted

Symptoms like nausea, vomiting, and diarrhea occurred more frequently in people taking GLP-1 drugs, with some studies reporting rates up to 17 percent higher than placebo